Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

Summary

The National Institutes of Health (NIH), through its Chemical Countermeasures Research Program (CCRP), is soliciting basic research proposals (R01 mechanism) to investigate the harmful physiological and biological effects of acute exposure to ultra-potent synthetic (UPS) opioids. Clinical trials are explicitly excluded from this funding opportunity. The initiative is intended to advance scientific understanding of UPS opioid toxicology to inform the development of medical countermeasures. The opportunity was posted in November 2024 and remains open through November 2027.

What they want

How they evaluate

• NIH peer review criteria: Significance
• NIH peer review criteria: Investigator(s)
• NIH peer review criteria: Innovation
• NIH peer review criteria: Approach
• NIH peer review criteria: Environment

Risks & flags

• Multi-year open window (2024–2027) with rolling submissions may limit competitive visibility for applicants unaware of the FOA
• Restriction to basic research (no clinical trials) and specific opioid class (UPS) narrows eligible applicant pool significantly